The European Society of Cardiology meeting kicked off in Barcelona over with weekend with better-than-expected data in the antiplatelet space from blockbuster Plavix (clopidogrel) and late-stage candidate Brilinta (ticagrelor), though the latest news struck another blow to Effient (prasurgrel), a recently approved blood thinner from Eli Lilly and Co. (BioWorld Today) Read More
